Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1994-07-20
1997-12-30
Elliott, George C.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
G01N 3353
Patent
active
057029083
ABSTRACT:
A method of identifying a compound which interferes with the binding of MDM2 to human p53 has been determined. This method comprises forming a mixture between MDM2 and a fragment of human p53 consisting of 6 to 28 amino acids comprising TFSDLW (SEQ ID NO:2), adding a test compound to the mixture and determining the quantity of protein bound to the other before and after adding the compound. A compound which decreases the amount of binding of the two proteins to each other is a compound which interferes with the binding of MDM2 to human p53.
REFERENCES:
Barak, Y., et al., "mdm2 expression is induced by wild type p53 activity," EMBO Journ., 12: pp. 461-468 (1993).
Barak, Y. & M. Oren, "Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest," EMBO Journ., 11: pp. 2115-2121 (1992).
Brown, D. R., et al., "The Tumor Suppressor p53 and the Oncoprotein Simian Virus 4D T Antigen Bind to Overlapping Domains on the MDM2 Protein," Molec. Cell. Biol., 13:pp. 6849-6857 (1993).
Cahilly-Snyder, L., et al., "Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line," Somatic Cell Mol. Genet., 13:pp. 235-244 (1987).
Chen, J., et al., "Mapping of the p53 and mdm-2 interaction domains," Mol. Cell. Biol., 13:pp. 4107-4114 (1993).
Dyson, W., et al., "Adenovirus E1A Makes Two Distinct Contacts with the Retinoblastoma Protein," J. Virol., 66:pp. 4606-4611 (1992).
Dyson, W., et al., "Homologous Sequences in Adenovirus E1A and Human Papillomavirus E7 Proteins Mediate Interaction with the Same Set of Cellular Proteins," J. Virol., 66:pp. 6893-6902 (1992).
Farmer, G. E., et al., "Wild-type p53 activates transcription in vitro," Nature, 358:pp. 83-86 (1992).
Funk, W. D., et al., "A transcriptionally active DNA binding site for human p53 protein complexes," Mol. Cell. Biol., 12:pp.2866-2871 (1992).
Kern, S. E., et al., "Oncogenic forms of p53 inhibit p53-regulated gene expression," Science, 256:pp. 827-830 (1992).
Michalovita, D., et al., "Conditional inhibition of transformation and of cell proliferation by c temperature-sensitive mutant of p53," Cell, 62:pp. 671-680 (1990).
Momand, J., et al., "The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated trans-activation," Cell, 69:pp. 1237-1245 (1992).
Oliner, J. D., et al., "Oncoprotein mdm2 conceals the activation domain of tumor suppressor p53," Nature, 362:pp. 857-860 (1993).
Unger, T., et al., "p53: A transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer," EMBO Journ., 11:pp. 1383-1390 (1992).
Picksley, S. M. & D. P. Lane, "The p53-mdm2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53," BioEssays, 15:p. 689 (1993).
Lin, J. et al., "Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 And the adeno virus 5 e1B 55-Kd protein," Genes & Develop., 8:pp. 1235-1246 (1994).
Schlichtholtz, B., et al., "The Immune Response to p53 in Breast Cancer Patients is Directed Against Immunodominant Epitopes Unrelated to Mutational Hot Spot," Canc. Res., 52:pp. 6380-6384 (1993).
Wu, X., et al., "The p53-mdm2 autoregulatory feedback loop," Genes & Develop., 7:pp. 1126-1132 (1993).
Picksley, S. M., et al,. "Immunochemical analysis of the interaction of p53 with MDM2;--the fine mapping of the MDM2 binding site on p53 using synthetic peptides," Oncogene, 9:pp. 2523-2530 (1994).
Deffie, A., et al., "The tumor suppressor p53 regulates its own transcription," Mol. Cell. Biol., 13:pp. 3415-3423 (1993).
Liu, X., et al., "The p53 activation domain binds the TATA box-binding polypeptide in holo-TF IID, and a neighboring p53 domain inhibits transcription," Mol. Cell. Biol., 13:pp. 3291-3300 (1993).
Oliner, J.D., et al, "Amplification of a gene encoding a p53-associated protein in human sarcomas," Nature 358:pp. 80-83 (1992).
Picksley, S. M. and Lane, D. P., "p53 and Rb: their cellular roles", Current Opinion in Cell Biology 6:pp. 853-858 (1994).
Martin, K., et al., "Stimulation of E2F1/DP1 Transcriptional Activity by MDM2 Oncoprotein," Nature 375:pp. 691-698 (1995).
Marston, N.J., et al., "Interaction of p53 with MDM2 is Independent of E6 and Does Not Mediate Wild Type Transformation Suppressor Function," Oncogene 9:pp.2707-2716 (1994).
Lane, D.P., et al., "On the Regulation of the p53 Tumour Suppressor, and its Role in the Cellular Response to DNA Damage," Phil. Trans. R. Soc. Lond. B 347:pp.83-87 (1995).
Lane David Philip
Picksley Steven Michael
Dreger Walter H.
Elliott George C.
McKelvey Terry A.
University of Dundee
LandOfFree
Interruption of binding of MDM2 and p53 protein and therapeutic does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interruption of binding of MDM2 and p53 protein and therapeutic , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interruption of binding of MDM2 and p53 protein and therapeutic will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-201364